

## **The Future of Inhaled Medicine**

**EGM Presentation** 

17th February 2023

## **Disclaimer**

This presentation contains summary information about InhaleRx Limited ("InhaleRx" or "IRX" or "Company") and its activities current as at the date of this presentation. It should be read in conjunction with InhaleRx' other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at <a href="https://www.asx.com.au">www.asx.com.au</a>

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire InhaleRx shares or other securities. It has been prepared without taking into account the objectives, financial situation or needs of individuals.

Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek legal and taxation advice appropriate to their jurisdiction. Past performance is no guarantee of future performance.

No representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of InhaleRx and its related bodies corporate, or their respective directors, employees or agents, nor any other person accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to InhaleRx' business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'plan', 'will', 'anticipate', 'expect', 'may', 'should' and similar expressions, as they relate to InhaleRx and its management, are intended to identify forward-looking statements.

Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of InhaleRx to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.



#### InhaleRx Overview

InhaleRx Ltd (IRX) is an Australian biotechnology company focused on the development of precision medicine delivered via inhalation.

We currently have two clinical programs across three clinical trials that will all commence this year.

IRX plan to open up new drug development programs in the inhalation sector to continue to address unmet clinical needs as new opportunities are identified.

# 'Leaders in the development of innovative inhaled therapeutics for the global health care market'.







#### **Executive Summary**

#### **Clinical Focus**

Mental Health and Pain.

#### Competitive Advantages

- World first development plans for inhalation drugs to target unmet clinical needs.
- Real word data from 10,000+ Australian patients across a wide range of indications.
- Carefully designed measured dose drug formulations.
- Leadership team with drug registration track record success.

#### Leading Programs & Traction

- Two programs running in parallel.
- Formulation work complete and manufacturing commissioned.
- Phase 1 & Phase 2 (Complex Regional Pain Syndrome), Phase 2 (Panic Disorder) all scheduled to commence this calendar year.

**IP** and Protection Innovation composition patent Patent No. 2021101157 approved for synthetic cannabinoids delivery via inhalation.



#### The InhaleRx Board of Directors



#### **YnhaleRx**

## **YnhaleRx**



at Senzer



John Crock

Non-executive Director

- Mr John Crock is a Board certified Plastic and Reconstructive surgeon.
- Senior Lecturer in the department of surgery Monash University, Melbourne Australia. He continues to supervise PhD students in various aspect of the surgical discipline.
- He founded, and is the director of, the NGO "Aussie Health Abroad" which focuses on training surgeons in developing nations.







### The InhaleRx Management Team



YnhaleRx

**Dr. Rob Jenny Chief Scientific Officer** 

- PhD trained scientist with significant experience in the commercialisation of research. project manufacturing and business development.
- Worked with a number of universities, biotech start-ups and contract manufacturers.
- As Chief Scientific Officer he manages the regulatory affairs activities, and oversees the preparation and execution of the nonclinical and clinical studies.



## **YnhaleRx**

management,

pharmaceutical

#### **Dr. Sud Agarwal**

Medical Science Consultant

- Dr Agarwal is an anaesthetist and a Co-Founder of Cannvalate
- Global expert and global cannabis key opinion leader advocating for clinically-validated cannabinoid treatment
- Significant experience in drug development and clinical validation (Multiple open IND)
- Previously the Chief Medical Officer at Incannex Healthcare Ltd.





## Inhalation innovation focused on solving unmet clinical needs

- InhaleRx has assembled an expert team to develop inhaled therapeutics to provide better health outcomes for patients.
- The company has a refined drug development plan across two cannabinoid drug assets with the overarching goal to achieve New Drug Approvals (NDA's) with U.S. Food & Drug Administration (FDA).

## Why develop novel targeted dose inhaled medications?


- Unlike oral, transdermal, or injectable delivery of pharmaceutical medicines, inhalation offers a unique combination of fast onset (and offset) of action, minimal invasiveness, high bioavailability, relatively low exposure, and ease of use for the patient.
- Most current pharmaceutical medicine delivery systems offer some, but not all of these benefits. -
- The administration via the inhaled route especially favours patient populations that are trying to manage acute episodes, such as breakthrough pain and anxiety.

#### **inhaleRx**





## Why inhaled therapies?



^ comparison of delivery methods only, different medications have different half-lives and not all medications are suitable for all delivery methods

#### **YnhaleRx**

### **Developing fast-acting inhaled therapies for underserved markets**



#### **Complex Regional Pain Syndrome (CRPS)**


A debilitating chronic pain syndrome characterised by paroxysmal breakthrough pain which needs immediate onset pain relief to manage.

#### **Panic Disorder (PD)**

A life-restricting, sudden, overwhelming anxiety syndrome which requires immediate onset anxiolysis to resolve unexpected episodes of panic.







## **Current assets under the development**

Single API Cannabinoid Pressurised Metered Dose Inhalers (pMDI)



Formulations developed for Panic Disorder (IRX616a) and Complex Regional Pain Syndrome (**IRX211**).



Drug suspensions formulated by using FDA-approved ingredients.



Finished dose form for clinical trials (IMP) manufactured in Australia under GMP.



IRX owns an innovation patent for the inhalation of synthetic cannabinoids.



Cannabinoid drug-device combinations undergoing clinical trials commencing 2023









## **Complex Regional Pain Syndrome (IRX211)**

**Prevalence:** 219,317<sup>1</sup> cases in the United States, the total (2017) - Confirmed Orphan Status TAM: USA: approx. **USD 7.08b**<sup>2</sup> (calculated by the prevalence x the average rebate under ODD) **Existing Drugs**: No drugs have been specifically approved for CRPS. Patients resort to combination of opioids/lyrica and atypical antidepressants. The sudden onset of pain and time to analgesic effect from current treatments is mismatched. **Reg Pathway:** FDA 505(b)(2) + Orphan Drug Designation (ODD)





### Panic Disorder (IRX616a)





## Notable progress across all three trials

Milestone	Phase 1 CRPS	Phase 2 PD	Phase 2 CRPS
Formulation complete	$\checkmark$	$\checkmark$	$\checkmark$
GMP Manufacturing commissioned	$\checkmark$	$\checkmark$	$\checkmark$
API in country	$\checkmark$	$\checkmark$	$\checkmark$
Site selected	$\checkmark$	$\checkmark$	$\checkmark$
Principle Investigator identified	$\checkmark$	$\checkmark$	$\checkmark$
Pre-IND meeting with the FDA		✓	
Ethics submission	$\checkmark$		
IND open			
First Patient In			





## 2023 milestones still to come

#### **Panic Disorder (IRX616a)**

- Ethics planned for Q1 2023.
- Manufacturing commissioned and scheduled to commence Q2 2023.
- Investigational New Drug (IND) submission expected before the end of the calendar year.
- First Patient In (FPI) planned for Q3 2023.

#### **Complex Regional Pain Syndrome (IRX211)**

- Ethics approval expected in Q1 for Phase 1. Phase 2 submission also planned for Q1 2023.
- Date for the Pre-IND meeting confirmed for end of Q1 2023.
- Manufacturing commissioned and scheduled to commence Q2 2023.
- Investigational New Drug (IND) submission expected before the end of the calendar year.
- First Patient In (FPI) for the Phase 1 planned for Q2 2023.
- First Patient In (FPI) for the Phase 2 planned for Q4 2023.



## Why the 505(b)(2) over standard New Drug Approval (NDA) pathway?



## **Faster approval process**

Relying on previously conducted studies can also result in a faster approval process as the FDA does not require the submission of extensive data typically required for a standard NDA. The 505(b)(2) pathway allows companies to rely on previously conducted studies, which can reduce the costs associated with conducting their own clinical trials.

#### YnhaleRx





## Cost savings



#### 505(b)(2) advantages continued



#### Reduced regulatory burden

The 505(b)(2) pathway may have a reduced regulatory burden compared to the standard NDA pathway, as the FDA does not require a full complement of preclinical and clinical studies.

The 505(b)(2) pathway provides more flexibility for companies to make changes or improvements to already approved drugs. This is because the FDA only requires that the new drug demonstrate improved safety, efficacy or other desired characteristics compared to the already approved drug.




## **inhaleRx**



## Increased flexibility

## **Traditional FDA Drug Approval Process**




5. https://www.optum.com/business/insights/pharmacy-care-services/page.hub.drug-approval-process.html





## FDA 505(b)(2) Pathway to Registration

Leveraging existing data reduces risk and cost



Time to approval - only 3 to 4.5 years (compared to the usual 10+ years)

#### **YnhaleRx**

## **YnhaleRx**

= Likely Key Inflection Points



#### **Benefits of creating value by submitting an IND**


- Submitting an IND application to the FDA is a significant step in developing a new drug.
- The value in opening an IND with the Food and Drug Administration (FDA) is that it provides a mechanism for a company to conduct clinical trials and gather data to support eventual approval for marketing the drug.
- If a drug is shown to be safe and effective through clinical trials, approval by the FDA can lead to increased access for patients in need and commercial success.
- Cleared IND results from efficient pre-clinical development operations and fluency in regulatory affairs.
- An IND application is a critical valuation determinant of publicly traded companies.
- 3 year data exclusivity once a New Drug Approval (NDA) is granted, 7 years with an Orphan Drug Designation (ODD).







#### Roadmap to open up IND's



## Formulation and device development

Formulation and device testing completed across both programs.

YnhaleRx

#### pIND

Occurred with FDA for CBD with positive feedback, THC is scheduled for end Q1 2023

#### Phase I & II Studies

Commenced proof of concept in human studies to resolve magnitude of effect.



#### **IND Open**

Investigational New Drug application opened with the FDA across both programs.



- World-first rapid onset treatments for carefully chosen acute conditions where there's currently a significant TAM and unmet medical need.
- 2023 is the execution phase across both clinical programs.
- Focused strategic direction to develop targeted dose inhaled drug delivery systems.
- Robust regulatory plan that involves opening IND's across both programs.
- Australian, U.K and Canadian institutions as part of the Top 20.



**Market Cap:** \$10.3M Stock Price: 0.6c Shares on Issue: 187.2m

# Thank you

- https://www.delveinsight.com/report-store/complex-regional-pain-syndrome
- https://rarediseases.org/wp-content/uploads/2021/03/orphan-drugs-in-the-united-states-NRD-2020.pdf
- 3. https://adaa.org/understanding-anxiety/facts-statistics
- https://pubmed.ncbi.nlm.nih.gov/16075454/
- 5. https://www.optum.com/business/insights/pharmacy-care-services/page.hub.drug-approval-process.html

#### InhaleRx Ltd (ASX:IRX) www.InhaleRx.com.au

Level 5, 126 Phillip Street, Sydney, NSW 2000



